| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.17 | 0.005 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.18 | 0.005 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.005 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.006 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.006 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.16 | 0.006 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.007 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.13 | 0.007 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.007 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |